Comparing Redhill Biopharma (RDHL) & Opexa Therapeutics (ACER)

Redhill Biopharma (NASDAQ: RDHL) and Opexa Therapeutics (NASDAQ:ACER) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Redhill Biopharma and Opexa Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma 0 0 4 0 3.00
Opexa Therapeutics 0 3 0 0 2.00

Redhill Biopharma presently has a consensus target price of $26.75, indicating a potential upside of 189.19%. Given Redhill Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Redhill Biopharma is more favorable than Opexa Therapeutics.

Volatility & Risk

Redhill Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Opexa Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Valuation and Earnings

This table compares Redhill Biopharma and Opexa Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Redhill Biopharma $583,000.00 272.31 -$41.03 million ($2.50) -3.70
Opexa Therapeutics N/A N/A N/A ($7.56) -2.36

Opexa Therapeutics has higher revenue, but lower earnings than Redhill Biopharma. Redhill Biopharma is trading at a lower price-to-earnings ratio than Opexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.0% of Redhill Biopharma shares are held by institutional investors. Comparatively, 36.7% of Opexa Therapeutics shares are held by institutional investors. 6.9% of Opexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Redhill Biopharma and Opexa Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Redhill Biopharma N/A -70.00% -57.98%
Opexa Therapeutics N/A -157.46% -106.61%


Redhill Biopharma beats Opexa Therapeutics on 7 of the 10 factors compared between the two stocks.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Opexa Therapeutics Company Profile

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply